EMBL European Bioinformatics Institute

Cancer cell
#Cancer drug targets #Drug resistance #EMBL European Bioinformatics Institute #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

Drug resistance study boosts discovery of next-generation cancer drugs

New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More

#Cancer Research #News #Trending News